[ad_1]
New Delhi: Pathology laboratory chain, Metropolis Healthcare has announced the completion of its acquisition of Kolhapur-based pathology laboratory chain, Ambika Pathology Laboratory for Rs 17 crore.
In August this year Metropolis had inked a Business Transfer Agreement (‘BTA’) with Dr. Rajendra Sadashiv Patil, a sole proprietor of Ambika Pathology Laboratory for the acquisition of his entire business consisting of pathology laboratories in Kolhapur, on a slump sale basis.
In a stock exchange filing the company had stated that, “of the total transaction amount of Rs 17 crore–Rs 1.7 crore is structured as deferred consideration and the entire payment will be made in cash.”
Ambika Pathology Laboratory is a NABL-accredited lab with a network of 12 patient touch points and generates 75 per cent of its revenue via B2C walk-in patients means.
Over the last three fiscals the regional chain reported a total turnover of Rs 7.96 crore (FY25), Rs 7.09 crore (FY24) and Rs 6.69 crore (FY23).
Commenting on the announcement Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare said, “Maharashtra accounts for nearly 40 per cent of the total revenues and the acquisition of Ambika Pathology further strengthens our Western Maharashtra cluster. Its regional presence makes it a natural fit within our expanding B2C network.”
Under its “String of Pearls” strategy the diagnostic chain is looking to build strong regional clusters and this marks the company’s fourth acquisition over the last 10 months
Metropolis’ last three acquisitions includes Dehradun-based Dr Ahuja’s Pathology, Scientific Pathology in Agra and Core Diagnostics which operates in Delhi NCR.
[ad_2]
Source link
